A Phase 3 interventional study of GT267-004 (tolevamer potassium sodium) in Enterocolitis, Pseudomembranous, Diarrhea and Clostridium Difficile, sponsored by Genzyme, a Sanofi Company. Terminated at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-19.
Sponsored by Genzyme, a Sanofi Company · Phase 3, Interventional, and Treatment
Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C. difficile-associated diarrhea (CDAD). All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is 6 weeks.
Exclusion Criteria:
Clinical Success
Safety
The extent of tolevamer absorption
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genzyme, a Sanofi Company